Sanofi GCVRZ 深 滬
等待開盤 10-08 09:30:00 美东时间
0.8711
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 總市值 1113.52亿
- 52周最高 0.882
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 總股本 1278.30亿
- 歷史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.153
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多J.P. Morgan Sticks to Its Hold Rating for Sanofi (SNYNF)
In a report released today, Richard Vosser from J.P. Morgan maintained a Hold r...
10-07 14:55
Regeneron sees nearly $0.18 per share earnings headwind after Sanofi deal
Days after announcing an expanded collaboration with its French partner Sanofi (SNY), Regeneron (REGN) on Tuesday disclosed that its net income per diluted share will be impacted by roughly $0.18 in Q...
10-06 21:25
Sanofi Publishes Q3 2026 Modelling Guide Ahead of Results
An announcement from Sanofi ( ($FR:SAN) ) is now available. Sanofi has made ava...
10-06 14:17
Sanofi Terminates Amlitelimab Asthma Extension Study: What Investors Should Watch
Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi’s l...
10-03 00:30
Medicare drug pricing model to affect only four firms after Trump’s MFN policy
A new Medicare payment model aimed at lowering prices for drugs administered in doctors’ offices may apply to only four pharmaceutical manufacturers after the industry struck multiple most-favored-nat...
10-02 19:32
House Democrats seek investigation into taxpayer-funded Trump ads
Two Democratic lawmakers are said to have called for independent probes into taxpayer-funded TV ads featuring President Donald Trump running ahead of the November midterm elections. Representative Jam...
10-01 17:41
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
Regeneron and Sanofi expand their antibody collaboration, adding four next-generation long-acting antibodies targeting IL-13, IL-4xIL-13, IL-4, and IL-4Rα. Regeneron will receive a $1 billion upfront payment, with potential for up to $7 billion in future milestone payments. The companies will equally share development and commercialization costs, as well as profits. REGN20423, a long-acting IL-13 monoclonal antibody, is currently in Phase 1 clini...
10-01 05:00
Sanofi’s Teplizumab Study Signals a New Front in Pediatric Type 1 Diabetes
Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi’s ...
09-30 00:30
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Wave Life Sciences appoints Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk brings extensive experience from Sanofi, Blackstone, and Pfizer in business development and strategic partnerships. She will lead business development, corporate development, and alliance management at Wave, supporting the company's growth and RNA medicines platform. Dr. Vnuk received a stock option to purchase 375,000 shares as part of her compensation.
09-22 11:30
药物受理最新动态：Sanofi-Aventis Recherche & DéveloppementSAR448632注射用粉末进口申请获受理
国家药品监督管理局药品审评中心数据显示，2026年9月21日，Sanofi-Aventis Recherche & Développement的SAR...
09-21 19:15
